<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26679">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759419</url>
  </required_header>
  <id_info>
    <org_study_id>18694</org_study_id>
    <secondary_id>2016-000501-36</secondary_id>
    <nct_id>NCT02759419</nct_id>
  </id_info>
  <brief_title>A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.</brief_title>
  <acronym>RIALTO</acronym>
  <official_title>An Open-label, Multi-national, Multi-center, Single-arm, Uncontrolled, Long-term Extension Study of Orally Administered Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH) Who Received Riociguat in a Bayer Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Provide riociguat therapy to patients with Pulmonary Arterial Hypertension (PAH) originating
      from the Bayer-sponsored trials 12935 PATENT-2 or 16719 RESPITE who are currently or
      recently treated in these trials until lack of patient benefit, or commercial availability
      and reimbursement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2016</start_date>
  <completion_date type="Anticipated">December 28, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment-emergent adverse events (TEAEs) as measure of safety and tolerability.</measure>
    <time_frame>Up to approx. 3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>BAY63-2521</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-arm, uncontrolled</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adempas (Riociguat, BAY63-2521)</intervention_name>
    <description>0.5 to 2.5 mg in 0.5 mg increments (according to individual adapted optimal dose determined in originating study) administered three times daily (tid)</description>
    <arm_group_label>BAY63-2521</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with Pulmonary Arterial Hypertension (PAH) participating or having
             participated in the Bayer-sponsored studies 12935 or 16719, who have completed the
             main study phase and are still being treated with riociguat (either while still being
             on treatment with the respective study drug or by commercial means with Adempas) and
             who, in the opinion of the investigator, are expected to continue to have an overall
             positive benefit/risk from continuing treatment.

          -  Women and men of reproductive potential must agree to use adequate contraception when
             sexually active. This applies for the time period between signing of the informed
             consent form and 30 days after the last administration of study drug.

        Exclusion Criteria:

          -  Ongoing serious adverse event (SAE) from originating study that is assessed as
             related to riociguat

          -  Pregnant women or breast-feeding women.

          -  Any contra-indication to Adempas treatment listed in the SmPC (Summary of Product
             Characteristics)

          -  Concomitant participation in another clinical study with the study drug.

          -  Patients with pulmonary Hypertension associated with idiopathic Interstitial
             pneumonia (PH-IIP)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Brest</city>
        <zip>F-29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Kremlin Bicetre Cedex</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 10, 2017</lastchanged_date>
  <firstreceived_date>April 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
